VISEN Pharmaceuticals (VISEN PHARMA-B) reported a share buyback executed on 16 June 2026, acquiring 7,700 ordinary shares on the Hong Kong Stock Exchange. The shares were repurchased at a high of HK$19.71 and a low of HK$19.31, giving a volume-weighted average price of HK$19.43 and a total consideration of HK$0.15 million.

Following the transaction, the number of issued shares outstanding (excluding treasury shares) fell by 0.007% to 113.78 million, while treasury shares increased to 0.15 million. Total issued share capital, including treasury shares, remained unchanged at 113.93 million.

The repurchase forms part of the mandate approved on 27 June 2025, which authorises the company to buy back up to 11.39 million shares. Cumulative repurchases under this mandate now stand at 148,400 shares, equivalent to 0.13% of the share count on the mandate date. Under listing rules, VISEN Pharma is restricted from issuing new shares or selling treasury shares until 16 July 2026.